Rosen Law Firm Investigates ADMA Biologics for Potential Securities Claims

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: 3 days ago

0mins

ADMA-0.64%

Should l Buy ADMA?

Source: PRnewswire

Securities Claims Investigation: Rosen Law Firm has announced an investigation into ADMA Biologics for potentially issuing materially misleading business information, which, if confirmed, could severely impact the company's reputation and stock price.
Stock Price Plunge: On March 24, 2026, ADMA Biologics shares fell by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, indicating a significant loss of market confidence in the company's financial transparency.
Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing affected shareholders to participate without any out-of-pocket fees, which could provide substantial economic compensation for those impacted.
Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong track record and success in the field, thereby enhancing investor trust in their representation.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ADMA

About ADMA

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Rosen Law Firm Investigates ADMA Biologics for Misleading Information

16 hours agoGlobenewswire

Securities Claims Investigation: Rosen Law Firm is investigating ADMA Biologics for potentially issuing materially misleading business information, which may expose shareholders to significant securities claims.
Stock Price Plunge: On March 24, 2026, ADMA Biologics' stock fell by 16.6% following allegations from short seller Culper Research that the company engaged in channel stuffing to inflate revenue growth, directly impacting investor confidence.
Class Action Preparation: The firm is preparing a class action to seek compensation for investor losses, with a contingency fee arrangement that allows investors to join without upfront costs, thereby reducing their legal risk.
Law Firm's Reputation: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.

ADMA Biologics Under Investigation for Securities Violations

1 day agoGlobenewswire

Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, urging investors to seek additional information regarding their legal options.
Revenue Growth Scrutiny: Allegations suggest that ADMA's reported 20% revenue growth in 2025 may have been artificially inflated through a channel stuffing scheme, raising concerns about the company's financial integrity and actual market demand.
Stock Price Plunge: Following a report from Culper Research that exposed these practices, ADMA's stock price plummeted by 29% over two trading days, from $13.59 to $9.63 per share, indicating significant market distrust in the company's financial disclosures.
Legal Implications: Investors may have legal recourse, as BFA offers representation on a contingency basis, emphasizing the firm's commitment to safeguarding shareholder interests amidst these serious allegations.